The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
Study Drug FDL169
Type of Study Drug CFTR modulator
Study Title A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation
Study Phase 1
Study Sponsor Flatley Discovery Lab LLC

Link on (link is external)

Participating ECFS-CTN sites Please contact for most recent sitelist
Age 18 years and older